The Food and Drug Administration has ordered new warning labels on popular GLP-1 drugs, including Novo Nordisk's Ozempic and Wegovy, due to a rare risk of permanent vision loss [1]. The FDA's advisory applies to a dozen pill-based and injectable GLP-1 drugs used to treat obesity, diabetes, and other medical conditions [1]. The eye condition in question is non-arteritic anterior ischemic optic neuropathy, which occurs when blood flow to the optic nerve is reduced, though its underlying cause remains unclear [1].
The FDA investigation began in 2024 after a study found that some patients taking semaglutide experienced vision loss [1]. The agency reviewed 126 clinical trials involving 134,253 patients and found that roughly six cases of the eye condition occurred per 100,000 patients taking GLP-1 drugs over a one-year period, compared with fewer than four cases among patients receiving a placebo or other glucose-lowering medications [1]. This represents a roughly 68% higher rate of developing the eye condition among GLP-1 drug users, though the FDA cautioned that the findings do not establish a causal link [1].
The FDA acknowledged significant challenges in determining causality, noting that risk factors for the condition—including diabetes, high blood pressure, and sleep apnea—are also common among patients prescribed GLP-1 drugs [1]. Of the roughly 78,000 patients included in the studies reviewed, just 10 experienced vision loss, representing approximately 0.01% of participants [1]. Non-arteritic anterior ischemic optic neuropathy is a rare condition with no proven treatment to reverse damage, though research has found that approximately 43% of patients with significant vision impairment experience some spontaneous improvement [1].
CONCLUSION
The FDA's new warning labels on GLP-1 drugs reflect a cautious regulatory approach to a rare but serious potential side effect, though the agency has not established definitive causality. With only 10 cases of vision loss among 78,000 trial participants (0.01%), the absolute risk remains extremely low, but the 68% higher incidence rate compared to control groups warrants physician and patient awareness. This regulatory action may create modest headwinds for GLP-1 drug manufacturers like Novo Nordisk, though the rarity of the condition is unlikely to significantly impact the blockbuster drug category's commercial trajectory.